News

Krebsliga awards the Robert Wenner prize to Davide Rossi at IOR

Swiss Cancer League - Krebsliga - has awarded the 2019 Robert Wenner Prize for young cancer researchers to Davide Rossi, Group leader at the Institute of Oncology Research (IOR, affiliated to Universi...

Inaugurata la nuova sede degli Istituti di ricerca scientifica IRB, IOR e EOC

Oltre 250 le persone presenti alla cerimonia del nuovo stabile di proprietà della Fondazione IRB Si è tenuta oggi la cerimonia d’inaugurazione ufficiale della nuova sede degli Istituti di ricerca s...

Video recording of the new building inauguration (27.11.2021)

The inauguration ceremony was held on Saturday 27.11.2021.  ...

A "jubilee grant" of the Helmut Horten Foundation awarded for research against lymphoma

On October 22, 2021, the Helmut Horten Foundation celebrated its 50th anniversary with a ceremony held at ETH Zurich. On this occasion, researchersDavide Rossiat the Institute of Oncology Research (IO...

Intestinal bacteria mechanism discovered at the IOR that could improve prostate cancer therapy

Scientists at the Institute of Oncology Research (IOR, affiliated to USI) and The Institute of Cancer Research, London, in collaboration with researchers from the University of Padova, have made a ver...

Engineered bacteria for cancer immunotherapy

A Nature paper by theSystems Immunologygroup, headed byRoger Geiger, at the Institute for Research in Biomedicine (IRB, affiliated to USI). This study describes an innovative strategy to improve the ...

New SNSF grants awarded to three IRB researchers

The Swiss National Science Foundation (SNSF) has recently awarded three group leaders at the Institute for Research in Biomedicine (IRB, affiliated to USI): Silvia Monticelli, Santiago González and Pe...

First peptide inhibitor of the CXCL12/HMGB1 heterocomplex identified

During inflammatory reactions, the production and release of chemotactic factors guide the recruitment of selective leukocyte subpopulations. The chemokine CXCL12 and the alarmin HMGB1, both released ...

IRB ready for clinical testing of second generation antibody against COVID-19

Following the development of a second-generation antibody against the novel coronavirus (SARS-CoV-2) and its variants, the Institute for Research in Biomedicine (IRB, affiliated to USI) is now mo...

IOR research project receives important funding from the United States

The American Society of Hematology (ASH) – the world’s leading association in the field of hematology – has awarded Dr. Adalgisa Condoluci, a researcher at the IOR, with the “ASH Global Research Award...

A Single Vaccine Against Coronaviruses is a step closer

The spillovers of β-coronaviruses in humans and the emergence of SARS-CoV-2 variants highlight the need for broad coronavirus countermeasures. A study co-authored by Dr. Jun Siong Low, Postdoc at t...

A molecular switch turns on the unfavorable evolution of prostate tumors

Researchers of the Prostate Cancer Biology group, directed by Giuseppina Carbone, M.D.  of the Institute of Oncology Research (IOR) discovered an unexpected mechanism that drives the evolution of...

Liver disease associated to alpha1-antitrypsin deficiency: a paper by Molinari’s lab

About 10% of the children with alpha1-antitrypsin deficiency must undergo liver transplantation. Their hepatocytes fail to properly degrade polymers of mutant alpha1-antitrypsin (ATZ), whose accumulat...

LICTOR, a new powerful tool to prevent systemic light-chain amyloidosis

Systemic light-chain amyloidosis (AL) is the most common form of a group of diseases associated with protein misfolding, leading to deposition of insoluble structures in different organs. Due to the...

New paper from the González’s lab

A paper from the González’s lab studies how to modify the innate immune response to improve the adaptive immunity against a potential HIV vaccine. To study this mechanism, we have employed the revolu...

A single new weapon against multiple viruses transmitted by ticks

 The bite of a tick can transmit Tick-Borne Encephalitis Virus (TBEV), which can cause brain infection, hospitalisation and long term neurologic problems. TBEV is only one among half a dozen vir...

Prestigious professorship awarded at the Institute of Oncology Research in Bellinzona

Stiftung Experimentelle Biomedizin has awarded Dr Arianna Calcinotto, Group Leader at the Institute of Oncology Research (IOR, affiliated to USI Università della Svizzera italiana) the Peter Hans...

The IRB joins international network for the study of emerging infectious diseases

The IRB announces it has joined the United World Antiviral Research Network (UWARN), the organisation that brings together researchers from leading institutions in several countries around the globe t...

IOR study reveals how breast cancer therapy may be effective against COVID-19

A study conducted by the Institute of Oncology Research (IOR, affiliated to USI) based on data obtained from the Veneto Tumor Registry (Italy) has observed a lower risk of developing the coronavirus d...

Why Specific Genetic Alterations Matter in Prostate Cancer

A given substance may be fundamental for life or may serve as a poison. All depends on the specific dose. At first glance, this somewhat paradoxical principle in medicine was first coined by the Swiss...

Circulating plasma extracellular vesicles give new insights for monitoring and managing disease progression in prostate cancer patients

The study by Albino et al. is published in Communications Biology and is available at https://doi.org/10.1038/s42003-020-01642-5. The work is a collaborative effort involving many rese...

Second generation antibody protects from SARS-CoV-2, its variant and prevents it from mutating to resist therapy

The Institute for Research in Biomedicine (IRB; Bellinzona, Switzerland), affiliated to the Università della Svizzera italiana (USI) developed a second-generation ‘double antibody’ that protects from ...

New Ebolavirus treatment sees the light thanks to basic research performed in Ticino

While populations around the world are being vaccinated against SARS-CoV-2, the U.S. Food and Drug Administration has announced the approval of a treatment against another well-known virus, much les...

Congratulations to Prof. Alimonti and his Molecular Oncology team on receiving the Prostate Cancer Foundation Challenge Award

Prof. Alimonti from the Institute of Oncology Research (IOR) in Bellinzona, Switzerland and Prof. De Bono from the Institute of Cancer Research (ICR) in London, United Kingdom, just received this pres...

IOR researchers suggest that androgen-deprivation treatments for prostate cancer could protect men from COVID-19

The so-called “androgen-deprivation” treatments used in prostate cancer therapy may have a protective effect against COVID-19. A study conducted by the Istitute of Oncology Research (IOR, affiliated ...

Press review